Intellectual Property

Confo holds the exclusive rights to its technology platform

Confo Therapeutics has exclusive rights to its proprietary Confo technology platform. The Confo® technology platform is protected by a broad patent portfolio, comprising more than 150 patent applications and granted patents in more than 10 patent families worldwide.

Confo’s IP estate includes exclusive worldwide licenses from the Flemish Institute of Biotechnology (VIB) in the field of GPCRs to the Steyaert patents for ConfoBodies® including applications for screening and three-dimensional structural analysis. In addition, Confo Therapeutics has additional patent protection around further developments of the technology.

“Our intellectual property is one of the cornerstones of our business, built through years of dedicated research and innovation by the team”

Frank Landolt | Chief Counsel, Intellectual Property and Legal

Work with us to revolutionize GPCR-directed medicines

Whether you are looking to understand our science, partner, or build your career with us, Confo offers unique opportunities for you to help bring novel medicines to patients.